A study evaluating prechemotherapy (pCRx) abiraterone acetate (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after ADT 1 Docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer: Multi-institution hospital-based registry
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Abiraterone acetate (Primary) ; Enzalutamide (Primary) ; Docetaxel
- Indications Prostate cancer
- Focus Therapeutic Use
- 13 Oct 2017 New trial record
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress